news

CUPERTINO, Calif., May 5 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) reported today that a pivotal Phase III program has been initiated for Remoxy(TM), an abuse-resistant pain medicine under development based on DURECT’s patented ORADUR(TM) technology incorporating the opioid oxycodone. The event was announced on May 4 by Pain Therapeutics, Inc. (Nasdaq: PTIE), DURECT’s licensee of […]

CUPERTINO, Calif., May 2 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended March 31, 2006. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ) DURECT’s net loss for the three months ended March 31, 2006 was $6.3 million or 10 cents per share, compared to a net loss of $5.4 million or 10 cents

CUPERTINO, Calif, May 2 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX), an emerging specialty pharmaceuticals company, announced today that Peter J. Langecker, M.D., Ph.D. has joined the Company as Chief Medical Officer. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO) “DURECT is committed to diligently moving its products through the clinical development stages. Further to that objective, we are very fortunate to

CUPERTINO, Calif., April 27 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX), an emerging specialty pharmaceuticals company, provided an update on its post-operative pain relief depot, SABER(TM)-Bupivacaine program. DURECT announced results from its Phase II Australian clinical study in hernia patients and the initiation of dosing in the first U.S. clinical trial, a Phase II, placebo-controlled trial

CUPERTINO, Calif., April 25, 2006 /PRNewswire-FirstCall via COMTEX News Network/ — In conjunction with DURECT Corporation’s (Nasdaq: DRRX) first quarter 2006 financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Tuesday, May 2nd, 2006 at 4:30 p.m. EDT. (Logo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO )

CUPERTINO, Calif., April 19 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the UBS Global Specialty Pharmaceuticals Conference. The conference is taking place April 24 – 25th at The Grand Hyatt Hotel in New York City, New York. Schond L. Greenway, Vice President, Investor Relations and Strategic Planning, will be

CUPERTINO, Calif., March 30 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference. The conference is taking place April 4-5th at The Millennium Broadway Hotel in New York City, New York. James E. Brown, DVM, President and Chief Executive Officer will

CUPERTINO, Calif., Feb. 17 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) reported today that Remoxy(TM), an abuse-resistant pain medicine under development based on DURECT’s patented ORADUR(TM) technology incorporating the opioid oxycodone has successfully completed a Special Protocol Assessment with the U.S. Food and Drug Administration (FDA) and that a pivotal Phase III trial is being commenced

CUPERTINO, Calif., Feb. 10 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the BIO CEO Investor Conference. The conference is being held at The Waldorf Hotel in New York, NY. Schond L. Greenway, Vice President, Investor Relations and Strategic Planning, will be presenting at the conference on February 15, 2006

CUPERTINO, Calif., Feb. 8 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today its financial results for the three months and year ended December 31, 2005. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ) Our net loss for the three months ended December 31, 2005 was $6.0 million or 10 cents per share, compared to a net loss of $7.0 million